US Patent Issued to Cedars-Sinai Medical Center on March 31 for "Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function" (American, Australian Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,160, issued on March 31, was assigned to Cedars-Sinai Medical Center (Los Angeles).

"Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function" was invented by David Q. Shih (La Crescenta, Calif.), Stephan R. Targan (Santa Monica, Calif.), Dalin Li (Walnut, Calif.) and Janine Bilsborough (Adelaide, Australia).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. ...